Navigation Links
Vanda Pharmaceuticals Reports Third Quarter 2008 Results
Date:10/30/2008

LIABILITIES AND STOCKHOLDERS' EQUITY

Current liabilities:

Accounts payable $899,035 $2,988,069

Accrued expenses 3,082,442 9,789,738

Total current liabilities 3,981,477 12,777,807

Long-term liabilities:

Deferred rent 496,774 354,042

Total liabilities 4,478,251 13,131,849

Stockholders' equity:

Common stock 26,653 26,653

Additional paid-in capital 270,279,679 257,600,368

Accumulated other comprehensive

income (loss) (241,814) 12,176

Deficit accumulated during the

development stage (217,470,488) (173,910,266)

Total stockholders' equity 52,594,030 83,728,931

Total liabilities and

stockholders' equity $57,072,281 $96,860,780

VANDA PHARMACEUTICALS INC.

(A Development Stage Enterprise)

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited)

Nine Months Ended

September 30, September 30,

2008 2007

Cash flows from operating activities:

Net loss $(43,560,222) $(53,321,284)

Adjustments to reconcile net income

to net cash used in operating

activities:

Depreciation and amortization 403,141 446,806

Stock-based compensation 12,679,311 14,480,108

Loss on disposal of assets (173) 2
'/>"/>

SOURCE Vanda Pharmaceuticals Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10

Related biology technology :

1. Vanda Pharmaceuticals Reports Fourth Quarter and Full Year 2007 Results
2. Vanda Pharmaceuticals to Present at the Bank of America 2008 Healthcare Conference
3. LabCorp(R) and Vanda Pharmaceuticals Collaborate to Offer Genetic Tests
4. Vanda Pharmaceuticals to Announce Second Quarter 2008 Financial Results on August 5, 2008
5. Vanda Pharmaceuticals Declares Dividend Distribution of Preferred Stock Purchase Rights
6. Vion Pharmaceuticals Pays Interest on 7.75% Convertible Senior Notes
7. China Biopharmaceuticals Holdings Announces Second Quarter 2007 Financial Results
8. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
9. XTL Biopharmaceuticals Announces Financial Results for the Six Months Ended June 30, 2007
10. Cadence Pharmaceuticals Reports Second Quarter 2007 Financial Results
11. Nabi Biopharmaceuticals to Present at Upcoming Industry Conferences
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/11/2014)... , Not for release, publication or distribution (in whole ... to do so would constitute a violation of the relevant ... the "Company") (LSE: SHP, NASDAQ: SHPG ) notes ... a meeting with representatives of AbbVie. This statement ... approval of AbbVie. A further update will be ...
(Date:7/11/2014)... July 11, 2014  Researchers have pioneered a ... The new technology, called Virtual Finger, allows scientists ... like neurons and synapses using the flat surface ... makes 3D imaging studies orders of magnitude more ... unprecedented level across many areas of experimental biology. ...
(Date:7/10/2014)... 10, 2014 Understanding the need for ... lines, and the gap that currently exists in this ... its industry-leading portfolio of validated ion channel and GPCR ... cell lines, as ion channels control many critical physiological ... activity creates the potential to treat a variety of ...
(Date:7/10/2014)... Montreal, QC (PRWEB) July 10, 2014 ... comfort and convenience. This rejuvenating device now comes with a ... that develops over time. , The new cup is thinner ... This design works to target rough, thin and uneven surfaces ... original firm cup for a stimulating treatment on areas such ...
Breaking Biology Technology:Shire plc - Statement re: Media Speculation 2Virtual Finger Enables Scientists To Navigate And Analyze 3D Images Of Complex Biological Structures 2Virtual Finger Enables Scientists To Navigate And Analyze 3D Images Of Complex Biological Structures 3Leader in Ion Channel Research Announces Newly Validated and Re-Engineered Cells 2Leader in Ion Channel Research Announces Newly Validated and Re-Engineered Cells 3Introducing a New Bonus Treatment Cup for EvoDerma’s NOOME Anti-Aging Motion 2
... 19, 2011 Advances that CSL Behring is ... therapeutic needs of patients with hemophilia A and B will ... medical congress on May 22, 2011. CSL Behring is a ... is a subsidiary of CSL Limited (ASX:CSL). ...
... May 19, 2011 Advantagene, Inc., a Massachusetts-based biopharmaceutical ... the U.S. Food and Drug Administration on a Special ... trial of ProstAtak™, its lead agent for patients with ... accrue 711 patients starting mid-2011 with definitive results expected ...
... 19, 2011 Reportlinker.com announces that a ... its catalogue: Global Biosimilars ... This report analyzes the worldwide ... report provides separate comprehensive analytics for US, ...
Cached Biology Technology:Overview of CSL Behring Innovations in Recombinant Technologies Presented at International Conference 2Overview of CSL Behring Innovations in Recombinant Technologies Presented at International Conference 3Advantagene Announces SPA Agreement With FDA to Launch Phase 3 Trial for Novel Vaccine Aimed at Preventing Prostate Cancer Recurrence 2Global Biosimilars Industry 2Global Biosimilars Industry 3Global Biosimilars Industry 4Global Biosimilars Industry 5Global Biosimilars Industry 6Global Biosimilars Industry 7Global Biosimilars Industry 8Global Biosimilars Industry 9Global Biosimilars Industry 10
(Date:7/11/2014)... Researchers have pioneered a revolutionary new way ... called Virtual Finger, allows scientists to move through ... synapses using the flat surface of their computer ... studies orders of magnitude more efficient, saving time, ... many areas of experimental biology. The software and ...
(Date:7/11/2014)... the hippocampus, the marginal division of the striatum ... is the impact degree of substance P in ... function? Yan Yu and his team, College of ... immunofluorescence staining, that substance P receptor, neurokinin 1 ... marginal division of normal rats. Unilateral or bilateral ...
(Date:7/11/2014)... 2014 Research and Markets has ... Market - Industry Analysis Size Share Growth Trends and ... http://photos.prnewswire.com/prnh/20130307/600769 The ... a need for high level security in both private ... such as username and passwords, tokens etc. are vulnerable ...
Breaking Biology News(10 mins):Virtual finger enables scientists to navigate and analyze complex 3D images 2International Biometrics Technology Market - Industry Analysis Size Share Growth Trends and Forecast to 2019 2
... calories leads to a longer life, scientists have proved. ... time that such a diet also can maintain physical ... to physical disability and loss of independence. The study, ... that the diet reduces the amount of visceral fat, ...
... to their social behavior, people sometimes act like monkeys, ... monkey that shares with humans strong tendencies for nepotism ... an expert on primate behavior and an Associate Professor ... University of Chicago. After humans, rhesus macaques are ...
... at Case Western Reserve Universitys School of Medicine ... remarkable discovery with a natural product derived from ... a broad set of applications in various joint, ... bowel syndrome., The publication revealed that Progrado, an ...
Cached Biology News:Severely restricted diet linked to physical fitness into old age 2Humans and monkeys share Machiavellian intelligence 2Humans and monkeys share Machiavellian intelligence 3Natural product discovery by Cleveland medical researchers blocks tissue destruction 2
... Cleland’s Reagent, Immobilized White solid. ... form of DTT on polyacrylamide resin with applications ... 233153 , 233156 , and ... no soluble components are added to the system. ...
... HVJ (hemagglutinating virus of Japan, also named ... tool for transfection of molecules by means ... for siRNA (RNAi), Protein, Oligo, cDNA, Antibodies, ... in vivo. GenomONE-Neo EX has a high ...
... White solid.. PACKAGED UNDER INERT GAS. Cyclizes as ... "driven" to completion. A protective agent for SH ... many other preparations. Blocks the lethal and hypnotic ... Contaminants: Heavy metals: ≤1 ppm. ...
... sequencing of Salmonella genomes has allowed the ... PCR* primer pairs. The S. enterica Typhimurium ... chromosome (4,857,432 bp; 4,440 ORFs) and a ... ORFmers from Sigma-Genosys have been designed to ...
Biology Products: